Collaboration - May 11, 2015
Pelago, OmicScouts Collaborate
Pelago Bioscience AB and OmicScouts GmbH launched a commercial and scientific collaboration involving the use of the Cellular Thermal Shift Assay (CETSA™) for determination and quantification of drug-target interactions, according to BioSpace.com. Under the agreement, Pelago Bioscience grants OmicScouts use licenses to the CETSA method for mass spectrometric and proteomic applications for contract research projects […]
Acquisition - May 10, 2015
AZ to Build Plant In Algeria
AstraZeneca is part of a joint venture to build a $125 million plant in North Africa. The company established AstraZeneca al-Djazair, with two companies in Algeria, Salhi and Hasnaoui, to construct the facility. Algerian law requires that local companies have the majority ownership, so AstraZeneca will have a 49 percent interest, invest the $125 million to […]
Business Award - May 9, 2015
SwedenBIO Award to Recipharm
For the ninth time, Recipharm has received the SwedenBIO Award. According to the announcement, “Recipharm has purposefully and with great skill built up a solid organization with a critical mass. A good revenue model not only has contributed to the company’s ability to create jobs in Sweden, but also to establish itself in the international […]
Acquisition - May 8, 2015
Gilead Buys EpiTherapeutics ApS
Gilead Sciences, Inc., has acquired EpiTherapeutics ApS for $65 million, subject to certain purchase price adjustments, to be financed through available cash on hand, according to FierceBiotech. EpiTherapeutics has a library of small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. The company’s lead pre-clinical compounds are being evaluated for the treatment of […]
Collaboration - May 8, 2015
Ardelyx, AZ to Review Agreement
Shares of Ardelyx dropped in after-market trading earlier this week after the AstraZeneca partner acknowledged that its lead drug tenapanor was unimpressive in a Phase IIa study. Ardelyx, based in California, says that tenapanor missed the primary endpoint among 154 patients with Stage 3 chronic kidney disease (CKD) and Type 2 diabetes, and was unable […]
Clinical Trials - May 8, 2015
Onxeo to Present Trial Results
Onxeo S.A.’s Validive®’s (clonidine Lauriad®) phase II clinical trial results have been accepted for an oral presentation at the MASCC/ISOO International Symposium scheduled for June 25-27 in Copenhagen. The company specializes in the development of orphan oncology drugs. The MASCC/ISOO Annual meeting focuses on supportive care for cancer patients and especially on therapeutic options to […]
